Cogent Biosciences (COGT) reported a second-quarter 2026 net loss of $96.4 million, compared with a net loss of $73.5 million in the same period of 2025. Research and development expenses rose to $70.8 million, while general and administrative expenses increased to $31.8 million.
The company said it had $792.3 million in cash, cash equivalents and marketable securities as of June 30, 2026. Including $73.6 million in gross proceeds from shares sold through its at-the-market facility after quarter-end, Cogent said its cash runway is expected to fund operations into late 2028.
- Cogent reported potential FDA approval timelines for bezuclastinib in GIST, with a PDUFA date of November 30, 2026, and NonAdvSM, with a PDUFA date of December 30, 2026.
- The company submitted a New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis on June 30.
- Second-quarter R&D expenses were $70.8 million, up from $62.2 million a year earlier.
- Second-quarter G&A expenses were $31.8 million, up from $13.4 million a year earlier.
- Cogent completed onboarding of its customer-facing commercial and medical team members.
$COGT Insider Trading Activity
$COGT insiders have traded $COGT stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $COGT stock by insiders over the last 6 months:
- FUNDS MANAGEMENT LLC FAIRMOUNT sold 7,000,000 shares for an estimated $242,619,999
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$COGT Hedge Fund Activity
We have seen 174 institutional investors add shares of $COGT stock to their portfolio, and 112 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FAIRMOUNT FUNDS MANAGEMENT LLC removed 3,500,000 shares (-38.9%) from their portfolio in Q1 2026, for an estimated $134,715,000
- GOLDMAN SACHS GROUP INC added 2,728,910 shares (+160.0%) to their portfolio in Q1 2026, for an estimated $105,035,745
- DUQUESNE FAMILY OFFICE LLC removed 2,214,470 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $85,234,950
- RTW INVESTMENTS, LP removed 2,133,566 shares (-28.1%) from their portfolio in Q1 2026, for an estimated $82,120,955
- KYNAM CAPITAL MANAGEMENT, LP removed 2,127,892 shares (-34.5%) from their portfolio in Q1 2026, for an estimated $81,902,563
- LORD, ABBETT & CO. LLC added 1,310,733 shares (+70.1%) to their portfolio in Q1 2026, for an estimated $50,450,113
- BLACKROCK, INC. added 1,307,632 shares (+8.1%) to their portfolio in Q2 2026, for an estimated $50,605,358
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
